Preclinical assessment of drug combinations for the treatment of pain: Isobolographic and dose-addition analysis of the opioidergic system

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 5, 2011, Pages 529-535

  Fischer, Bradford D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Analgesia; Dose addition; Drug combination; Isobologram; Opioid; Pain

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AMANTADINE; CLONIDINE; CODEINE; DELTA OPIATE RECEPTOR AGONIST; DIAMORPHINE; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; FENTANYL; GLUTAMATE RECEPTOR ANTAGONIST; JNJ16259685; LUMIRACOXIB; MELOXICAM; METHADONE; MORPHINE; MOXONIDINE; MSF61; NALBUPHINE; NIMESULIDE; OPIATE RECEPTOR; PARECOXIB; PETHIDINE; ROFECOXIB; SNC162; SNC80; TETRAHYDROCANNABINOL; TRAMADOL; UNCLASSIFIED DRUG;

ANALGESIA; ANTINOCICEPTION; ARTHRITIS; ARTICLE; DRUG BIOAVAILABILITY; DRUG COMBINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; NONHUMAN; PAIN; TAIL FLICK TEST; VISCERAL PAIN;

EID: 79960007383     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711796235050     Document Type: Article

References (53)

1. Lacroix-Fralish, M.L.; Ledoux, J.B.; Mogil, J.S. The Pain Genes Database: An interactive web browser of pain-related transgenic knockout studies. Pain, 2007, 131, 3.e1-3.e4.
2. Tallarida, R.J. Drug Synergism and Dose-Effect Data Analysis; Chapman & Hall/CRC Press: Boca Raton, FL., 2000.
3. Grabovsky, Y.; Tallarida, R.J. Isobolographic analysis for combinations of a full and partial agonist: curved isoboles. J. Pharmacol. Exp. Ther., 2004, 310, 981-986.
4. Tallarida, R.J. Interactions between drugs and occupied receptors. Pharmacol. Ther., 2007, 113, 197-209.
5. Raffa, R.B.; Pergolizzi, J.V.; Tallarida R.J. The determination and application of fixed-dose analgesic combinations for treating multimodal pain. J. Pain, 2010, 11, 701-709.
6. Loewe, S. The problem of synergism and antagonism of combined drugs. Arzneimittelforsch, 1953, 3, 285-290.
7. Bliss, C.I. The toxicity of poisons applied jointly. Ann. Appl. Biol., 1939, 26, 585-615.
8. Finney, D.J. The analysis of toxicity tests on mixtures of poisons. Ann. Appl. Biol., 1942, 29, 82-94.
9. Gessner, P.K.; Cabana, B.E. A study of the interaction of the hypnotic effects and of the toxic effects of chloral hydrate and ethanol. J. Pharmacol. Exp. Ther., 1970, 174, 247-259.
10. Raffa, R.B.; Stagliano, G.W.; Tallarida, R.J. Nonlinear isobologram and superadditive withdrawal from cocaine: cannabinoid combinations in planarians. Eur. J. Pharmacol., 2007, 556, 89-90.
11. Pircio, A.W.; Buyniski, J.P.; Roebel, L.E. Pharmacological effects of a combination of butorphanol and acetaminophen. Arch. Int. Pharmacodyn., 1978, 235, 116-123.
12. Maves, T.J.; Pechman, P.S.; Meller, S.T.; Gebhart, G.F. Ketorolac potentiates morphine antinociception during visceral nociception in the rat. Anesthesiology, 1994, 80, 1094-1101.
13. Tallarida, R.J.; Raffa, R.B. Testing for synergism over a range of fixed ratio drug combinations: replacing the isobologram. Life Sci., 1996, 58, 23-28.
14. Miranda, H.F.; Prieto, J.C.; Pinardi, G. Spinal synergy between nonselective cyclooxygenase inhibitors and morphine antinociception in mice. Brain Res., 2005, 1049, 165-170.
15. Ortiz, M.I.; Ponce-Monter, H.; Fernández-Martínez, E.; Pérez-Hernández, N.; Macías, A.; Rangel-Flores, E.; Castañeda-Hernández, G. Evaluation of the interaction between acemetacin and opioids on the hargreaves model of thermal hyperalgesia. Pharmacol. Biochem. Behav., 2007, 88, 47-54.
16. Capuano, A.; De Corato, A.; Treglia, M.; Tringali, G.; Dello Russo, C.; Navarra, P. Antinociceptive activity of buprenorphine and lumiracoxib in the rat orofacial formalin test: a combination analysis study. Eur. J. Pharmacol., 2009, 605, 57-62.
17. Ortiz, M.I.; Castañeda-Hernández, G. Examination of the interaction between peripheral lumiracoxib and opioids on the 1% formalin test in rats. Eur. J. Pain, 2008, 12, 233-241.
18. Pinardi, G.; Prieto, J.C.; Miranda, H.F. Analgesic synergism between intrathecal morphine and cyclooxygenase-2 inhibitors in mice. Pharmacol. Biochem. Behav., 2005, 82, 120-124.
19. Déciga-Campos, M.; López, U.G.; Reval, M.I.; López-Muñoz, F.J. Enhancement of antinociception by co-administration of an opioid drug (morphine) and a preferential cyclooxygenase-2 inhibitor (rofecoxib) in rats. Eur. J. Pharmacol., 2003, 460, 99-107.
20. Satyanarayana, P.S.; Jain, N.K.; Singh, A.; Kulkarni, S.K. Isobolographic analysis of interaction between cyclooxygenase inhibitors and tramadol in acetic acid-induced writhing in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28, 641-649.
21. García-Hernández, L.; Déciga-Campos, M.; Guevara-López, U.; López-Muñoz, F.J. Co-administration of rofecoxib and tramadol results in additive or sub-additive interaction during arthritic nociception in rat. Pharmacol. Biochem. Behav., 2007, 87, 331-340.
22. Jasmin, L.; Boudah, A.; Ohara, P.T. Long-term effects of decreased noradrenergic central nervous system innervation on pain behavior and opioid antinociception. J. Comp. Neurol., 2003, 460, 38-55.
23. Ossipov, M.H.; Harris, S.; Lloyd, P.; Messineo, E. An isobolographic analysis of the antinociceptive effect of systemically and intrathecally administered combinations of clonidine and opiates. J. Pharmacol. Exp. Ther., 1990a, 255, 1107-1116.
24. Ossipov, M.H.; Harris, S.; Lloyd, P.; Messineo, E.; Lin, B.S.; Bagley, J. Antinociceptive interaction between opioids and medetomidine: systemic additivity and spinal synergy. Anesthesiology, 1990b, 73, 1227-1235.
25. Przesmycki, K.; Dzieciuch, J.A.; Czuczwar, S.J.; Kleinrok, Z. Isobolographic analysis of interaction between intrathecal morphine and clonidine in the formalin test in rats. Eur. J. Pharmacol, 1997, 337, 11-17.
26. Pinardi, G.; Pelissier, T.; Miranda, H.F. Interactions in the antinociceptive effect of tramadol in mice: an isobolographic analysis. Eur. J. Pain, 1998, 2, 343-350.
27. Fairbanks, C.A.; Nguyen, H.O.; Grocholski, B.M.; Wilcox, G.L. Moxonidine, a selective imidazoline-alpha2 -adrenergic receptor agonist, produces spinal synergistic antihyperalgesia with morphine in nerve-injured mice. Anesthesiology, 2000, 93, 765-773.
28. Fairbanks, C.A.; Posthumus, I.J.; Kitto, K.F.; Stone, L.S.; Wilcox, G.L. Moxonidine, a selective imidazoline/alpha(2) adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice. Pain, 2000, 84, 13-20.
29. Sudo R.T.; Calasans-Maia J.A.; Galdino S.L.; Lima M.C.; Zapata-Sudo G.; Hernandes M.Z.; Pitta I.R. Interaction of morphine with a new alpha2-adrenoceptor agonist in mice. J. Pain, 2010, 11, 71-78.
30. O'Neill, S.J.; Collins, M.A.; Pettit, H.O.; McNutt, R.W.; Chang, K.J. Antagonistic modulation between the delta opioid agonist BW373U86 and the mu opioid agonist fentanyl in mice. J. Pharmacol. Exp. Ther., 1997, 282, 271-277.
31. Su, Y.F.; McNutt, R.W.; Chang, K.J. delta-Opioid ligands reverse alfentanil-induced respiratory depression but not antinociception. J. Pharmacol. Exp. Ther., 1998, 287, 815-823.
32. Adams, J.U.; Tallarida, R.J.; Geller, E.B.; Adler, M.W. Isobolographic superadditivity between delta and mu opioid agonists in the rat depends on the ratio of compounds, the mu agonist and the analgesic assay used. J. Pharmacol. Exp. Ther., 1993, 266, 1261-1267.
33. Horan P.; Tallarida R.J.; Haaseth R.C.; Matsunaga T.O.; Hruby V.J.; Porreca F. Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. Life Sci., 1992, 50, 1535-1541.
34. Stevenson, G.W.; Folk, J.E.; Linsenmayer, D.C.; Rice, K.C.; Negus, S.S. Opioid interactions in rhesus monkeys: effects of δ + μ and δ + K agonists on schedule-controlled responding and thermal nociception. J. Pharmacol. Exp. Ther., 2003, 307, 1054-1064.
35. Banks M.L.; Folk J.E.; Rice K.C.; Negus S.S. Selective enhancement of fentanyl-induced antinociception by the delta agonist SNC162 but not by ketamine in rhesus monkeys: further evidence supportive of delta agonists as candidate adjuncts to mu opioid analgesics. Pharmacol. Biochem. Behav., 2010, 97, 205-212.
36. Stevenson, G.W.; Folk, J.E.; Rice, K.C.; Negus, S.S. Interactions between δ and μ I Opioid Agonists in Assays of Schedule-Controlled Responding, Thermal Nociception, Drug Self-Administration, and Drug versus Food Choice in Rhesus Monkeys: Studies with SNC80 [(+)-4-[(aR)-a-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide] and Heroin. J. Pharmacol. Exp. Ther., 2005, 314, 221-231.
37. Negus, S.S.; Bear, A.E.; Folk, J.E.; Rice, K.C. Role of delta opioid efficacy as a determinant of mu/delta opioid interactions in rhesus monkeys. Eur. J. Pharmacol, 2009, 602, 92-100.
38. Nishiyama, T. Interaction between intrathecal morphine and glutamate receptor antagonists in formalin test. Eur. J. Pharmacol, 2000, 395, 203-210.
39. Snijdelaar, D.G.; van Rijn, CM.; Vinken, P.; Meert, T.F. Effects of pre-treatment with amantadine on morphine induced antinociception during second phase formalin responses in rats. Pain, 2005, 119, 159-167.
40. Fischer, B.D.; Dykstra, L.A. Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception. J. Pharmacol. Exp. Ther., 2006, 318, 1300-1306.
41. Pelissier, T.; Laurido, C; Kramer, V.; Hernández, A.; Paeile, C. Antinociceptive interactions of ketamine with morphine or methadone in mononeuropathic rats. Eur. J. Pharmacol, 2003, 477, 23-28.
42. Alvarez, P.; Saavedra G.; Hernández A.; Paeile C.; Pelissier T. Synergistic antinociceptive effects of ketamine and morphine in the orofacial capsaicin test in the rat. Anesthesiology 2003, 99, 969-975.
43. Malyshkin, A.A.; Medvedev, I.O.; Danysz, W.; Bespalov, A.Y. Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine in neuropathic rats. Eur. J. Pharmacol., 2005, 519, 80-85.
44. Fischer, B.D.; Zimmerman, E.I.; Picker, M.J.; Dykstra, L.A. Morphine in combination with metabotropic glutamate receptor antagonists on schedule-controlled responding and thermal nociception. J. Pharmacol. Exp. Ther., 2008, 324, 732-739.
45. Cichewicz, D.L.; McCarthy, E.A. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J. Pharmacol. Exp. Ther., 2003, 304, 1010-1015.
46. Tham, S.M.; Angus, J.A.; Tudor, E.M.; Wright, C.E. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br. J. Pharmacol., 2005, 144, 875-884.
47. Cox, M.L.; Haller, V.L.; Welch, S.P. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur. J. Pharmacol., 2007, 567, 125-130.
48. Trujillo, K.A.; Akil, H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 1991, 251, 85-87.
49. Allen, R.M.; Dykstra, L.A. Attenuation of mu-opioid tolerance and cross-tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY235959 is related to tolerance and cross-tolerance magnitude. J. Pharmacol. Exp. Ther., 2000, 295, 1012-1021.
50. Kozela, E.; Pilc, A.; Popik, P. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-D-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology, 2003, 165, 245-251.
51. Smith, F.L.; Smith, P.A.; Dewey, W.L.; Javed, R.R. Effects of mGlu1 and mGlu5 metabotropic glutamate antagonists to reverse morphine tolerance in mice. Eur. J. Pharmacol., 2004, 492, 137-142.
52. Cichewicz, D.L.; Welch, S.P. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 2003, 305, 812-817.
53. Fischer, B.D.; Ward, S.J.; Henry, F.E.; Dykstra, L.A. Attenuation of morphine antinociceptive tolerance by a CB(1) receptor agonist and an NMDA receptor antagonist: Interactive effects. Neuropharmacology, 2010, 58, 544-550.